Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD1 | P21728 | 15/20 | 0.50 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17224056 | 0.84 | DRD1 (0.64) | DRD1 | |
| SCHEMBL17224060 | 0.82 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17224062 | 0.82 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17228687 | 0.82 | DRD1 (0.41) | DRD1KDM4EALDH1A1HPGD | |
| SCHEMBL17228544 | 0.82 | DRD1 (0.49) | DRD1PDE10AMAP4K4 | |
| SCHEMBL17228548 | 0.81 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17224063 | 0.81 | DRD1 (0.60) | DRD1 | |
| SCHEMBL17228781 | 0.76 | DRD1 (0.55) | DRD1 | |
| SCHEMBL17228681 | 0.76 | DRD1 (0.45) | DRD1 | |
| SCHEMBL17224039 | 0.76 | DRD1 (0.61) | DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | claimed |
| EP-3137454-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2017-03-08 | — | — | EP | claimed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | claimed |
| WO-2015166370-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | claimed |
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| US-9856263-B2 | Heteroaromatic compounds and their use as dopamine D1 ligands | PFIZER INC. (US) | 2018-01-02 | — | — | US | disclosed |
| EP-3137454-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | Pfizer Inc. (US) | 2017-03-08 | — | — | EP | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2017-02-09 | — | — | US | disclosed |
| WO-2015166370-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| WO-2015166370-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | PFIZER INC. (US) | 2015-11-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170037049-A1 | HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS | DRD2, DRD1, DRD4 | DRD1 2/4885PDE10A 1575/4885KDM4E 4663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.